Compare Stocks: SNGX, ATOS, ESLA, and JSPR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.05 -6.0%	$2.44	$1.70 ▼ $19.35	$20.46M	1.27	117,697 shs	37,214 shs
ESLA Estrella Immunopharma	$0.47 -0.2%	$0.70	$0.46 ▼ $3.15	$20.49M	0.88	99,109 shs	9,160 shs
JSPR Jasper Therapeutics	$0.59 +3.3%	$0.70	$0.32 ▼ $2.69	$19.48M	3.04	855,990 shs	634,167 shs
SNGX Soligenix	$0.39 +0.3%	$0.38	$0.28 ▼ $1.97	$5.73M	1.92	2.73 million shs	228,598 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-3.54%	-9.92%	-17.42%	+23.16%	-82.34%
ESLA Estrella Immunopharma	-2.68%	-26.24%	-35.78%	-50.32%	-60.00%
JSPR Jasper Therapeutics	-9.01%	-2.43%	-21.54%	+28.00%	-76.38%
SNGX Soligenix	+0.03%	+6.97%	-4.84%	-2.51%	-80.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.05 -6.0%	$2.44	$1.70 ▼ $19.35	$20.46M	1.27	117,697 shs	37,214 shs
ESLA Estrella Immunopharma	$0.47 -0.2%	$0.70	$0.46 ▼ $3.15	$20.49M	0.88	99,109 shs	9,160 shs
JSPR Jasper Therapeutics	$0.59 +3.3%	$0.70	$0.32 ▼ $2.69	$19.48M	3.04	855,990 shs	634,167 shs
SNGX Soligenix	$0.39 +0.3%	$0.38	$0.28 ▼ $1.97	$5.73M	1.92	2.73 million shs	228,598 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-3.54%	-9.92%	-17.42%	+23.16%	-82.34%
ESLA Estrella Immunopharma	-2.68%	-26.24%	-35.78%	-50.32%	-60.00%
JSPR Jasper Therapeutics	-9.01%	-2.43%	-21.54%	+28.00%	-76.38%
SNGX Soligenix	+0.03%	+6.97%	-4.84%	-2.51%	-80.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	2.20	Hold	$20.33	891.87% Upside
ESLA Estrella Immunopharma	2.00	Hold	$8.00	1,598.51% Upside
JSPR Jasper Therapeutics	2.29	Hold	$7.33	1,152.70% Upside
SNGX Soligenix	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SNGX, ATOS, ESLA, and JSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/8/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$2.00
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$2.00
8/11/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	JSPR Jasper Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	SNGX Soligenix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/7/2026	ATOS Atossa Genetics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$4.57 per share	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	($0.27) per share	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A
SNGX Soligenix	N/A	N/A	N/A	N/A	$0.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$34.77M	-$3.11	N/A	N/A	N/A	N/A	-102.99%	-85.78%	11/11/2026 (Estimated)
ESLA Estrella Immunopharma	-$13.06M	-$0.24	N/A	N/A	N/A	N/A	N/A	-328.72%	12/2/2026 (Estimated)
JSPR Jasper Therapeutics	-$75.80M	-$1.59	N/A	N/A	N/A	N/A	-884.17%	-143.83%	11/9/2026 (Estimated)
SNGX Soligenix	-$11.08M	-$0.98	N/A	N/A	N/A	N/A	-180.25%	-107.46%	11/6/2026 (Estimated)

Latest SNGX, ATOS, ESLA, and JSPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	JSPR Jasper Therapeutics	-$0.2678	-$0.10	+$0.1678	-$0.10	N/A	N/A
8/13/2026	Q2 2026	ESLA Estrella Immunopharma	-$0.09	-$0.05	+$0.04	-$0.05	N/A	N/A
8/7/2026	Q2 2026	ATOS Atossa Genetics	-$1.02	-$0.95	+$0.07	-$0.95	N/A	N/A
8/7/2026	Q2 2026	SNGX Soligenix	-$0.1550	-$0.12	+$0.0350	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
SNGX Soligenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	5.69	5.14
ESLA Estrella Immunopharma	N/A	0.20	0.20
JSPR Jasper Therapeutics	N/A	1.48	1.47
SNGX Soligenix	N/A	2.77	2.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
ESLA Estrella Immunopharma	0.35%
JSPR Jasper Therapeutics	79.85%
SNGX Soligenix	3.60%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	9.80%
ESLA Estrella Immunopharma	5.80%
JSPR Jasper Therapeutics	3.90%
SNGX Soligenix	1.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	14	9.98 million	9.00 million	Optionable
ESLA Estrella Immunopharma	N/A	43.50 million	40.98 million	Not Optionable
JSPR Jasper Therapeutics	22	33.28 million	31.98 million	Optionable
SNGX Soligenix	14	14.82 million	14.54 million	Not Optionable

SNGX, ATOS, ESLA, and JSPR Headlines

Recent News About These Companies

Financial Review: Cartesian Therapeutics (NASDAQ:RNAC) versus Soligenix (NASDAQ:SNGX)

September 22 at 5:15 AM | americanbankingnews.com

Soligenix (NASDAQ:SNGX) vs. Pliant Therapeutics (NASDAQ:PLRX) Financial Review

September 18, 2026 | americanbankingnews.com

SNGX: Applying for Vaccine Development Funding for Ebola Vaccine

August 12, 2026 | finance.yahoo.com

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

August 7, 2026 | prnewswire.com

Soligenix Expands At-the-Market Equity Offering Capacity

June 26, 2026 | tipranks.com

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

June 8, 2026 | prnewswire.com

Soligenix Expands At-The-Market Equity Financing Capacity

May 28, 2026 | tipranks.com

SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy

May 27, 2026 | finance.yahoo.com

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

May 26, 2026 | prnewswire.com

SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026 | finanznachrichten.de

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026 | prnewswire.com

SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment

April 29, 2026 | msn.com

SNGX phase 3 trial halted on HyBryte

April 29, 2026 | msn.com

SOLIGENIX, INC.: Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma

April 28, 2026 | finanznachrichten.de

SNGX phase 3 trial halted — HyBryte setback puts strategy in question

April 28, 2026 | msn.com

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

April 28, 2026 | prnewswire.com

Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

April 23, 2026 | finance.yahoo.com

Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

April 23, 2026 | usatoday.com

Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

April 20, 2026 | financial-news.co.uk

Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

April 20, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SNGX, ATOS, ESLA, and JSPR Company Descriptions

Atossa Genetics NASDAQ:ATOS

$2.05 -0.13 (-5.96%)

Closing price 04:00 PM Eastern

Extended Trading

$2.07 +0.02 (+0.78%)

As of 06:25 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Estrella Immunopharma NASDAQ:ESLA

$0.47 0.00 (-0.21%)

Closing price 03:59 PM Eastern

Extended Trading

$0.48 +0.00 (+0.85%)

As of 04:04 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Jasper Therapeutics NASDAQ:JSPR

$0.59 +0.02 (+3.28%)

Closing price 04:00 PM Eastern

Extended Trading

$0.57 -0.02 (-2.80%)

As of 06:16 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Soligenix NASDAQ:SNGX

$0.39 +0.00 (+0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$0.39 +0.01 (+1.50%)

As of 05:33 PM Eastern

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNGX, ATOS, ESLA, and JSPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNGX, ATOS, ESLA, and JSPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNGX, ATOS, ESLA, and JSPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SNGX, ATOS, ESLA, and JSPR Company Descriptions

Atossa Genetics NASDAQ:ATOS

Estrella Immunopharma NASDAQ:ESLA

Jasper Therapeutics NASDAQ:JSPR

Soligenix NASDAQ:SNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNGX, ATOS, ESLA, and JSPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNGX, ATOS, ESLA, and JSPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNGX, ATOS, ESLA, and JSPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SNGX, ATOS, ESLA, and JSPR Company Descriptions

Atossa Genetics NASDAQ:ATOS

Estrella Immunopharma NASDAQ:ESLA

Jasper Therapeutics NASDAQ:JSPR

Soligenix NASDAQ:SNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools